

Witness Name: Mr Andrew John Furlong

Statement No.: WITN3073001

Exhibits: WITN3073002- WITN3073007

Dated: 6 June 2019

---

**EXHIBIT WITN3073006**

**Email correspondence between Professor Martin Wiselka and others, various  
dates in August 2016**

---

**Kurmoo Feza - Staff Nurse**

**From:** Wiselka Martin - Professor of Infectious Diseases  
**Sent:** 23 August 2016 15:05  
**To:** Dey Joanne - Pharmacist  
**Cc:** Kurmoo Feza - Staff Nurse; Iliffe Mariesa - Nurse Specialist; Garg Mamta - Consultant Haematologist  
**Subject:** RE: Maria Fletcher : S2777509

Dear Jo

Neutropenia is very rare with ribavirin and isn't mentioned on the product information so I do not think this is a particular concern. However, haemoglobinopathy is cited as a contra-indication to ribavirin, even though she has had it previously.

Overall probably best to omit ribavirin

Martin

---

**From:** Dey Joanne - Pharmacist  
**Sent:** 23 August 2016 14:40  
**To:** Wiselka Martin - Professor of Infectious Diseases  
**Cc:** Kurmoo Feza - Staff Nurse; Iliffe Mariesa - Nurse Specialist  
**Subject:** FW: Maria Fletcher : S2777509

Dear Martin

This patient who has beta thalassaemia major is taking an iron chelator called deferiprone. Deferiprone can cause neutropenia in 5% of patients and agranulocytosis in 1% of patients – the mechanism is unknown. The manufacturer recommends that patients should not take other medicines associated with neutropenia or that can cause agranulocytosis.

Please see note below regarding ribavirin and Feza tells me that the patient is very keen to have ribavirin. She has taken it and tolerated it previously but at that time she was not on deferiprone. She has previously taken sc Desferal as an alternative to deferiprone and so if we are keen to use ribavirin then we may need to speak to Dr. Garg regarding her switching to this for the duration of treatment.

Regards  
 Jo

---

**From:** Kenney Sue - MDT Co-ordinator  
**Sent:** 17 August 2016 13:26  
**To:** Kurmoo Feza - Staff Nurse  
**Cc:** Dey Joanne - Pharmacist  
**Subject:** Maria Fletcher : S2777509

Hi Feza

Just to let you know that Maria Fletcher has now been approved for treatment with Harvoni for 12 weeks. Dr Forton (ODN partner) has added a comment "if you think she is cirrhotic and can tolerate haemolysis, I would add Ribavirin too". Geraldine Linehan (Commissioner) has approved this patient for treatment.

As requested, I have requested this patient's hospital notes (x 2 sets) to be delivered to you, and marked the request as urgent for tomorrow.

06/09/2016

860

P860  
 WITN3073006\_0002

With kind regards

**GRO-C**

Sue Kenney  
MDT Co-ordinator  
Infectious Diseases - Leicester Royal Infirmary  
University Hospitals of Leicester NHS Trust  
Tel: **GRO-C**  
(Working Days : Monday – Thursday)

06/09/2016

861

**D861**  
WITN3073006\_0003